Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:BPMC NASDAQ:MIRM NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$10.06B1.252.19 million shs2.09 million shsBPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/AMIRMMirum Pharmaceuticals$74.31-2.2%$62.19$36.86▼$78.10$3.82B0.92736,079 shs336,390 shsVRNAVerona Pharma PLC American Depositary Share$106.43+0.0%$104.80$27.54▼$106.45$8.71B0.141.25 million shs918,692 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-2.64%-4.07%+1.65%+28.73%+82.96%BPMCBlueprint Medicines0.00%0.00%0.00%+1.17%+49.56%MIRMMirum Pharmaceuticals-2.21%-2.30%+14.08%+49.73%+77.31%VRNAVerona Pharma PLC American Depositary Share+0.03%+0.11%+1.17%+15.43%+253.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$51.21-2.6%$48.54$21.72▼$54.60$10.06B1.252.19 million shs2.09 million shsBPMCBlueprint Medicines$129.46$128.90$73.04▼$129.65$8.36B0.891.55 million shsN/AMIRMMirum Pharmaceuticals$74.31-2.2%$62.19$36.86▼$78.10$3.82B0.92736,079 shs336,390 shsVRNAVerona Pharma PLC American Depositary Share$106.43+0.0%$104.80$27.54▼$106.45$8.71B0.141.25 million shs918,692 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-2.64%-4.07%+1.65%+28.73%+82.96%BPMCBlueprint Medicines0.00%0.00%0.00%+1.17%+49.56%MIRMMirum Pharmaceuticals-2.21%-2.30%+14.08%+49.73%+77.31%VRNAVerona Pharma PLC American Depositary Share+0.03%+0.11%+1.17%+15.43%+253.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$63.9424.86% UpsideBPMCBlueprint Medicines 2.11Hold$130.000.42% UpsideMIRMMirum Pharmaceuticals 3.11Buy$74.440.18% UpsideVRNAVerona Pharma PLC American Depositary Share 2.14Hold$109.002.41% UpsideCurrent Analyst Ratings BreakdownLatest MIRM, BBIO, BPMC, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025BBIOBridgeBio PharmaUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $82.009/12/2025MIRMMirum PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $77.009/3/2025BBIOBridgeBio PharmaJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$55.00 ➝ $70.008/29/2025BBIOBridgeBio PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.008/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $89.008/8/2025VRNAVerona Pharma PLC American Depositary ShareZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy8/7/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetMarket Outperform$79.00 ➝ $81.008/7/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetStrong-Buy$77.00 ➝ $82.008/7/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$73.00 ➝ $80.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$235.81M41.52N/AN/A($7.71) per share-6.64BPMCBlueprint Medicines$562.12M14.87N/AN/A$4.70 per share27.54MIRMMirum Pharmaceuticals$336.89M11.08N/AN/A$4.70 per share15.81VRNAVerona Pharma PLC American Depositary Share$221.67M39.29N/AN/A$2.56 per share41.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%10/28/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,547.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest MIRM, BBIO, BPMC, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08BPMCBlueprint Medicines1.012.802.75MIRMMirum Pharmaceuticals1.213.132.97VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BPMCBlueprint MedicinesN/AMIRMMirum PharmaceuticalsN/AVRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BPMCBlueprint Medicines4.21%MIRMMirum Pharmaceuticals14.36%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableVRNAVerona Pharma PLC American Depositary Share3081.83 million82.34 millionOptionableMIRM, BBIO, BPMC, and VRNA HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 12-Month High - Should You Buy?September 12 at 10:22 AM | marketbeat.comHere’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12 at 8:51 AM | insidermonkey.comFred Alger Management LLC Lowers Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 12 at 5:20 AM | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Sold by Octagon Capital Advisors LPSeptember 11 at 6:03 AM | marketbeat.comScientech Research LLC Takes Position in Verona Pharma PLC American Depositary Share $VRNASeptember 10 at 5:43 AM | marketbeat.comInvesco Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNASeptember 10 at 3:02 AM | marketbeat.comTemasek Holdings Private Ltd Makes New $2.01 Million Investment in Verona Pharma PLC American Depositary Share $VRNASeptember 9, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 8, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes Position in Verona Pharma PLC American Depositary Share $VRNASeptember 8, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Acquired by Duquesne Family Office LLCSeptember 6, 2025 | marketbeat.comEventide Asset Management LLC Reduces Stake in Verona Pharma PLC American Depositary Share $VRNASeptember 6, 2025 | marketbeat.comCinctive Capital Management LP Purchases New Position in Verona Pharma PLC American Depositary Share $VRNASeptember 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Stake Raised by Boothbay Fund Management LLCSeptember 6, 2025 | marketbeat.com160,000 Shares in Verona Pharma PLC American Depositary Share $VRNA Bought by Cutter Capital Management LPSeptember 6, 2025 | marketbeat.comAllostery Investments LP Invests $794,000 in Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Buys Shares of 139,067 Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comState of Wyoming Invests $291,000 in Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Boosts Position in Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stock Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comVestal Point Capital LP Sells 227,373 Shares of Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMIRM, BBIO, BPMC, and VRNA Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$51.21 -1.39 (-2.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.71 +1.50 (+2.93%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Blueprint Medicines NASDAQ:BPMCBlueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$74.31 -1.68 (-2.21%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$74.31 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.43 +0.03 (+0.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$106.19 -0.24 (-0.23%) As of 09/12/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
